文献速递骨软组织肉瘤与黑色素瘤

PD-L1是转移性黑色素瘤中抗CTLA-4联合抗PD-1或抗PD-1单药治疗真实世界临床结局的生物标志物

PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma.
PubMed 文献 · Eur J Cancer · 2023-12-12

基于丹麦人群的队列研究纳入1341例转移性黑色素瘤患者,其中1081例已知PD-L1状态(43% PD-L1≥1%,57% PD-L1<1%)。PD-L1≥1%是全队列生存的独立正向预后标志物(MSS:HR 0.66,CI 0.52-0.83,p<0.001)。在倾向性匹配评分PD-L1≥1%队列中,联合治疗与单药治疗的临床结局相似;而在PD-L1<1%及PD-L1<1% BRAF野生型队列中,联合治疗改善PFS,但MSS和OS未达统计学显著改善。

要点

  • PD-L1≥1%是全队列生存的独立正向预后标志物(MSS:HR 0.66,CI 0.52-0.83,p<0.001)。
  • 倾向性匹配评分PD-L1≥1%队列中,联合治疗与单药治疗PFS、MSS、OS均无显著差异。
  • 倾向性匹配评分PD-L1<1%及PD-L1<1% BRAF野生型队列中,联合治疗改善PFS,但MSS和OS未达统计学显著。

核心结论

  • 研究结果支持Checkmate-067既往探索性分析,强调在未选择的肿瘤PD-L1高表达(≥1%)患者中,联合治疗改善临床结局尚未确立。

研究设计与样本

  • 基于丹麦人群的队列研究,纳入2017年1月以来在丹麦接受一线联合治疗或抗PD-1单药治疗的所有转移性黑色素瘤患者(除外眼黑色素瘤),共识别1341例 eligible 患者,其中1081例已知PD-L1状态。
  • 采用多变量分析和倾向性匹配评分(PMS)分析,评估PD-L1表达与无进展生存期(PFS)、黑色素瘤特异性生存期(MSS)和总生存期(OS)的关系。

主要发现

  • 1081例已知PD-L1状态的患者中,43%为PD-L1≥1%,57%为PD-L1<1%。
  • PD-L1≥1%是全队列生存的独立正向预后标志物(MSS:HR 0.66,CI 0.52-0.83,p<0.001)。
  • 在PMS PD-L1≥1%队列中,联合治疗与单药治疗的临床结局相似(PFS:HR 1.41,CI 0.94-2.11,p=0.101;MSS:HR 1.21,CI 0.70-2.11,p=0.49;OS:HR 1.17,CI 0.68-2.00,p=0.567)。
  • 在PMS PD-L1<1%队列中,联合治疗较单药治疗改善PFS(HR 0.70,CI 0.53-0.93,p=0.013),但MSS(HR 0.72,CI 0.50-1.02,p=0.065)和OS(HR 0.78,CI 0.56-1.08,p=0.135)未达统计学显著改善。
  • 在PMS PD-L1<1% BRAF野生型队列中,联合治疗较单药治疗改善PFS(HR 0.54,CI 0.37-0.78,p=0.001),但MSS(HR 0.79,CI 0.51-1.21,p=0.278)和OS(HR 0.81,CI 0.54-1.21,p=0.305)未达统计学显著改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression. METHODS: We conducted a population-based study including all patients with MM (except ocular melanoma) treated in Denmark with first-line combination therapy or anti-PD-1 monotherapy since January 2017. Baseline data including known prognostic characteristics were used in multivariable and propensity-matched score (PMS) analyses to assess progression-free survival (PFS), melanoma-specific survival (MSS), and overall survival (OS) according to PD-L1 expression. RESULTS: We identified 1341 eligible patients, with known PD-L1 status for 1081 patients (43% PD-L1 ≥ 1%, 57% PD-L1 < 1%). PD-L1 ≥ 1% was an independent positive prognostic biomarker for survival in the overall cohort (MSS: HR 0.66, CI 0.52-0.83, p < 0.001). In the PMS PD-L1 ≥ 1% cohort, combination therapy showed similar clinical outcomes to monotherapy (PFS: HR 1.41, CI 0.94-2.11, p = 0.101; MSS: HR 1.21, CI 0.70-2.11, p = 0.49; OS: HR 1.17, CI 0.68-2.00, p = 0.567). In contrast, in the PMS PD-L1 < 1% and in the PMS PD-L1 < 1% BRAF WT cohorts, combination therapy improved PFS (respectively with HR 0.70, CI 0.53-0.93, p = 0.013; and HR 0.54, CI 0.37-0.78, p = 0.001), but did not reach statistically significant improvements of MSS (HR 0.72, CI 0.50-1.02, p = 0.065; and HR 0.79, CI 0.51-1.21, p = 0.278) or OS (HR 0.78, CI 0.56-1.08, p = 0.135; and HR 0.81, CI 0.54-1.21, p = 0.305) compared to monotherapy. CONCLUSION: Our findings support previous exploratory analyses of Checkmate-067, highlighting that improved clinical outcomes with combination therapy are not established in unselected patients with high (≥1%) tumor PD-L1 expression.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ellebaek E, Khan S, Bastholt L, et al. PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma. Eur J Cancer. 2023. PMID: 38171116. doi:10.1016/j.ejca.2023.113476

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。